ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
A phase 3 trial testing Rocbrutinib in chronic lymphocytic leukaemia, now recruiting.
Overview
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL is a phase 3 interventional study registered as NCT07342478, led by Newave Pharmaceutical, and recruiting when checked on 2026-09-11. Official title: A Phase 3 Open-Label, Randomised, Multicenter Study of Rocbrutinib (LP-168) vs Pirtobrutinib in Covalent BTK Inhibitor (cBTKi) Pretreated Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL) Subjects. Planned enrolment is 306 participants (estimated). The study started in 2026-04-23 and primary completion is expected in 2029-10-30. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Shares Rocbrutinib and the tag ctgov-ingest.
- TrialA Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Shares Chronic lymphocytic leukaemia and the tag ctgov-ingest.
- TrialStudy of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
Shares Chronic lymphocytic leukaemia and the tag ctgov-ingest.
- TrialICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
Shares Chronic lymphocytic leukaemia and the tag ctgov-ingest.
- TreatmentDZD8586
Shares Chronic lymphocytic leukaemia and the tag ctgov-ingest.
- TreatmentCTX112
Shares Chronic lymphocytic leukaemia and the tag ctgov-ingest.
- TreatmentBexobrutideg
Shares Chronic lymphocytic leukaemia and the tag ctgov-ingest.
- TreatmentICP-248
Shares Chronic lymphocytic leukaemia and the tag ctgov-ingest.